

555049

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096853 A1

(51) International Patent Classification⁷: **C07K 14/595**,
14/50, A61K 38/33, 38/18, C12N 15/09, A01K 67/027,
A61P 3/10

CRUZ, Antonio [CA/CA]; 89 Dunloe Road, Toronto, On-
tario M5P 2T7 (CA).

(21) International Application Number:
PCT/CA2004/000648

(74) Agents: **KURDYDYK, Linda et al.**; Suite 4700, Box 48,
66 Wellington Street West, Toronto Dominion Bank Tower,
Toronto, Ontario M5K 1E6 (CA).

(22) International Filing Date: 30 April 2004 (30.04.2004)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/509,068 30 April 2003 (30.04.2003) US

(71) Applicant (*for all designated States except US*):
WARATAH PHARMACEUTICALS, INC. [CA/CA];
415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7
(CA).


(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BRAND, Stephen J.**,
[AU/US]; 161 Bedford Road, Lincoln, MA 01773 (US).

[Continued on next page]

(54) Title: COMBINED USE OF KERATINOCYTE GROWTH FACTOR AGONISTS AND GASTRIN COMPOUNDS



(57) Abstract: The invention relates generally to compositions, conjugates, and methods comprising a KGF agonist and a gastrin compound. The compositions can be used in the treatment and/or prevention of conditions for which either a KGF agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, metabolic syndrome and related diseases and disorders, and obesity.

WO 2004/096853 A1



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.